Valproic acid and HIV-1 latency: beyond the sound bite.
A recent publication in Lancet by Dr. David Margolis and colleagues raised the prospect that HIV infection may be curable. In this pilot study, which received much attention from the press, Dr. Margolis'group found that valproic acid plus enfuvirtide reduces the pool of CD4+ T-cells, which are latently infected with HIV-1, the so-called viral reservoir. This commentary critically addresses current data on this topic.
Smith
Stephen M
SM
Department of Medicine, Saint Michael's Medical Center, The New Jersey Medical School, Newark, New Jersey 07102, USA. ssmith1824@aol.com
D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D014635:Valproic Acid / Q000494:pharmacology*; D017735:Virus Latency / Q000187:drug effects*
D014635:Valproic Acid